A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma

Summary

The purpose of this study is to find out whether the combination of botensilimab and balstilimab (BOT/BAL) is a safe and effective treatment that causes few or mild side effects for people with mismatch repair proficient (MMRp)/microsatellite stable (MSS) locally advanced rectal adenocarcinoma. The investigators will also find out whether BOT/BAL is an effective treatment when given in combination with standard chemotherapy.

Timeline

Start

2025-02-20

Primary completion

2028-02-20

Completion

2028-02-20

Drugs

Indications